welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Study of SRP-4045 and SRP-4053 in DMD Patients
study id #: NCT02500381
condition: Duchenne Muscular Dystrophy
status: recruiting
purpose:The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053 compared to placebo in Duchenne muscular dystrophy (DMD) patients with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.
intervention: SRP-4045, SRP-4053, Placebo
mechanism of action: Exon-skipping to promote dystrophin production
results: https://clinicaltrials.gov/ct2/show/results/NCT02500381
last updated: September 19, 2020
rareRelated
-
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation DystrophinopathyThe primary objective of this study is t...
-
PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical TrialPTC Therapeutics, Inc. is seeking pa...
-
Open Label Study of GSK2402968 in Subjects With Duchenne Muscular DystrophyThe purpose of this study is to explore ...
-
Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular DisordersThe hypothesis is that a mechanical insu...
-
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Musc...This is a multi-center, randomized, doub...
-
A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy (REACH-DMD)The purpose of this study is to evaluate...
-
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patie...Sarepta Therapeutics, Inc., a leader in ...
-
ICER Releases Draft Evidence Report on Treatments for Duchenne Muscular DystrophyThe Institute for Clinical and Economic ...
-
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
-
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...